Tumor Biology

, Volume 37, Issue 2, pp 2635–2645 | Cite as

Tumor necrosis factor superfamily member 13 is a novel biomarker for diagnosis and prognosis and promotes cancer cell proliferation in laryngeal squamous cell carcinoma

  • Ru Wang
  • Yichao Guo
  • Hongzhi Ma
  • Lin Feng
  • Qi Wang
  • Xiaohong Chen
  • Meng Lian
  • Haizhou Wang
  • Jugao Fang
Original Article


Tumor necrosis factor superfamily member 13 (TNFSF13) modulates cell proliferation and apoptosis and participates in the pathogenesis of solid tumors, but its role in laryngeal cancer development is not clearly defined. In order to investigate whether TNFSF13 can be used as a biomarker for diagnosis and prognosis in laryngeal squamous cell carcinoma (LSCC) and the role of TNFSF13 in laryngeal cancer carcinogenesis, we conducted immunohistochemistry and ELISA assays to evaluate the expression level of TNFSF13 in laryngeal cancer patients and the contrast. We also conducted experiments on the functional study of TNFSF13 in vitro. We found that the expression levels of TNFSF13, ki-67, and NF-κB p65 in LSCC tumor tissues were higher than those in vocal polyp and para-carcinoma tissues. The Spearman rank correlation analysis showed that the expression of TNFSF13 had a positive correlation with the expression of ki-67 and NF-κB p65. Cox regression analysis and Kaplan–Meier plots confirmed the expression level of TNFSF13 was a prognostic factor for LSCC. Moreover, the serum TNFSF13 level was significantly higher in LSCC patients than in the controls, and the serum expression level of TNFSF13 can distinguish LSCC from healthy people, precancerosis, or laryngeal benign tumor. In addition, functional study of TNFSF13 in vitro revealed that knockdown of TNFSF13 inhibited cell proliferation by inducing G1 phase cell cycle arrest in Hep-2 cells. In conclusion, TNFSF13 may be a potential novel molecular target for diagnosis and prognosis in human LSCC, and therapies that target TNFSF13 may have clinical significance for the treatment of LSCC.


Laryngeal neoplasms TNFSF13 ki-67 NF-κB p65 Biomarker 



This work was supported by the Beijing Municipal Science & Technology Commission Program (No. Z141107002514003), the Beijing Municipal Administration of Hospitals Clinical Medicine Development of special funding support (Code: XMLX201311), and the National Natural Science Foundation of China (No. 81072204).

Compliance with ethical standards

All patients provided informed consent before their participation. Ethical approval was given by the medical ethics committee of the Ethics Committee of Beijing Tongren Hospital with the following reference number: TRECKY2010-KS02. The study was undertaken in accordance with the ethical standards of the World Medical Association Declaration of Helsinki.

Conflicts of interest



  1. 1.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CACancer J Clin. 2009;59(4):225–49.CrossRefGoogle Scholar
  2. 2.
    Vokes EE, Stenson KM. Therapeutic options for laryngeal cancer. N Engl J Med. 2003;349(22):2087–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917. doi: 10.1002/ijc.25516.J].CrossRefPubMedGoogle Scholar
  4. 4.
    Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood. 2012;119(3):651–65. doi: 10.1182/blood-2011-04-325225.].CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Planelles L, Medema JP, Hahne M, Hardenberg G. The expanding role of APRIL in cancer and immunity. Curr Mol Med. 2008;8(8):829–44.CrossRefPubMedGoogle Scholar
  6. 6.
    Dillon SR, Gross JA, Ansell SM, Novak AJ. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov. 2006;5(3):235–46.CrossRefPubMedGoogle Scholar
  7. 7.
    Soneoka Y, Cannon PM, Ramsdale EE, Griffiths JC, Romano G, Kingsman SM, et al. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res. 1995;23(4):628–33.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Sakoda T, Kasahara N, Hamamori Y, Kedes L. A high-titer lentiviral production system mediates efficient transduction of differentiated cells including beating cardiac myocytes. J Mol Cell Cardiol. 1999;31(11):2037–47.CrossRefPubMedGoogle Scholar
  9. 9.
    Tiscornia G, Singer O, Verma IM. Production and purification of lentiviral vectors. Nat Protoc. 2006;1(1):241–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Zhou Y, Ma H, Fang J, Lian M, Feng L, Wang R. Knockdown of CUG-binding protein 1 induces apoptosis of human laryngeal cancer cells. Cell Biol Int. 2014;38(12):1408–14. doi: 10.1002/cbin.10356.CrossRefPubMedGoogle Scholar
  11. 11.
    He F, Li J, Xu J, Zhang S, Xu Y, Zhao W, et al. Decreased expression of ARID1A associates with poor prognosis and promotes metastases of hepatocellular carcinoma. J Exp Clin Cancer Res. 2015;34:47. doi: 10.1186/s13046-015-0164-3.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Wang G, Wang F, Ding W, Wang J, Jing R, Li H, et al. APRIL induces tumorigenesis and metastasis of colorectal cancer cells via activation of the PI3K/Akt pathway. PLoS One. 2013;8(1), e55298. doi: 10.1371/journal.pone.0055298.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Cui JW, Li Y, Wang C, Yao C, Li W. Knockdown of a proliferation-inducing ligand (PRIL) suppresses the proliferation of gastric cancer cells. Asian Pac J Cancer Prev. 2012;13(2):633–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Mhawech-Fauceglia P, Allal A, Odunsi K, Andrews C, Herrmann FR, Huard B. Role of the tumour necrosis family ligand APRIL in solid tumour development: retrospective studies in bladder, ovarian and head and neck carcinomas. Eur J Cancer. 2008;44(15):2097–100. doi: 10.1016/j.ejca.2008.07.007.CrossRefPubMedGoogle Scholar
  15. 15.
    Mhawech-Fauceglia P, Kaya G, Sauter G, McKee T, Donze O, Schwaller J, et al. The source of APRIL up-regulation in human solid tumor lesions. J Leukoc Biol. 2006;80(4):697–704.CrossRefPubMedGoogle Scholar
  16. 16.
    Qian Z, Qingshan C, Chun J, Huijun Z, Feng L, Qiang W, et al. High expression of TNFSF13 in tumor cells and fibroblasts is associated with poor prognosis in non-small cell lung cancer. Am J Clin Pathol. 2014;141(2):226–33. doi: 10.1309/AJCP4JP8BZOMHEAW.CrossRefPubMedGoogle Scholar
  17. 17.
    Ding W, Wang J, Wang F, Wang G, Wu Q, Ju S, et al. Serum sAPRIL: a potential tumor-associated biomarker to colorectal cancer. Clin Biochem. 2013;46(15):1590–4. doi: 10.1016/j.CrossRefPubMedGoogle Scholar
  18. 18.
    Bojarska-Junak A, Hus I, Chocholska S, Wasik-Szczepanek E, Sieklucka M, Dmoszynska A, et al. BAFF and APRIL expression in B-cell chronic lymphocytic leukemia: correlation with biological and clinical features. Leuk Res. 2009;33(10):1319–27. doi: 10.1016/j.leukres.2009.03.030.CrossRefPubMedGoogle Scholar
  19. 19.
    Lian M, Fang J, Han D, Ma H, Wang R, Yang F. The up-regulation expression of APRIL is a marker of glottic malignant disease. Eur Arch Otorhinolaryngol. 2014;271(10):2781–7. doi: 10.1007/s00405-013-2826-0.CrossRefPubMedGoogle Scholar
  20. 20.
    Yu G, Boone T, Delaney J, Hawkins N, Kelley M, Ramakrishnan M, et al. APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Nat Immunol. 2000;1(3):252–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Hahne M, Kataoka T, Schroter M, Hofmann K, Irmler M, Bodmer JL, et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med. 1998;188(6):1185–90.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Szczepanski MJ, Czystowska M, Szajnik M, Harasymczuk M, Boyiadzis M, Kruk-Zagajewska A, et al. Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res. 2009;69(7):3105–13.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Jackson-Bernitsas DG, Ichikawa H, Takada Y, Myers JN, Lin XL, Darnay BG, et al. Evidence that TNF-TNFR1-TRADD-TRAF2-RIP-TAK1-IKK pathway mediates constitutive NF-kappaB activation and proliferation in human head and neck squamous cell carcinoma. Oncogene. 2007;26(10):1385–97.CrossRefPubMedGoogle Scholar
  24. 24.
    Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182(3):311–22.CrossRefPubMedGoogle Scholar
  25. 25.
    Moreaux J, Veyrune JL, De Vos J, Klein B. APRIL is overexpressed in cancer: link with tumor progression. Bmc Cancer. 2009;9:83. doi: 10.1186/1471-2407-9-83.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    García-Castro A, Zonca M, Florindo-Pinheiro D, Carvalho-Pinto CE, Cordero A, Gutiérrez del Fernando B, et al. APRIL promotes breast tumor growth and metastasis and is associated with aggressive basal breast cancer. Carcinogenesis. 2015;36(5):574–84. doi: 10.1093/carcin/bgv020.CrossRefPubMedGoogle Scholar
  27. 27.
    Wang J, Ding W, Sun B, Jing R, Huang H, Shi G, et al. Targeting of colorectal cancer growth, metastasis, and anti-apoptosis in BALB/c nude mice via APRIL siRNA. Mol Cell Biochem. 2012;363(1-2):1–10. doi: 10.1007/s11010-011-1151-4.CrossRefPubMedGoogle Scholar
  28. 28.
    Wang F, Chen L, Ni H, Wang G, Ding W, Cong H, et al. APRIL depletion induces cell cycle arrest and apoptosis through blocking TGF-β1/ERK signaling pathway in human colorectal cancer cells. Mol Cell Biochem. 2013;383(1-2):179–89. doi: 10.1007/s11010-013-1766-8.CrossRefPubMedGoogle Scholar
  29. 29.
    Park MT, Lee SJ. Cell cycle and cancer. J Biochem Mol Biol. 2003;36(1):60–5.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Ru Wang
    • 1
  • Yichao Guo
    • 1
  • Hongzhi Ma
    • 1
    • 2
  • Lin Feng
    • 1
    • 2
  • Qi Wang
    • 1
    • 2
  • Xiaohong Chen
    • 1
    • 2
  • Meng Lian
    • 1
  • Haizhou Wang
    • 1
  • Jugao Fang
    • 1
    • 2
    • 3
  1. 1.Department of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren HospitalCapital Medical UniversityBeijingChina
  2. 2.Key Laboratory of Otorhinolaryngology Head and Neck Surgery, Ministry of EducationBeijing Institute of OtorhinolaryngologyBeijingChina
  3. 3.Beijing Key Laboratory of Head and Neck Molecular Diagnostic PathologyBeijingChina

Personalised recommendations